Karah Herdman Parschauer
Known title: EVP and General CounselCIK: 0001677455
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Evolus (EOLS) Passes Momentum Screens. Evolus Inc. has recently met the criteria for the Minervini Trend Template and a high growth momentum screen. This suggests the stock is showing signs of upward price strength and volume activity. While the company trades well below its average analyst target price, these technical signals indicate a shift in trading patterns.
Transaction History
| RARE | ▼ Sell | Open Market | 1,900 | $47K | 8/3/2026 | View on chart |
| RARE | ▼ Sell | Open Market | 1,899 | $47K | 6/15/2026 | View on chart |
| RARE | ▲ Buy | Grant | 28,895 | $0 | 4/16/2026 | View on chart |
| RARE | ▼ Sell | Open Market | 3,508 | $80K | 3/10/2026 | View on chart |
| RARE | ▼ Sell | Open Market | 6,018 | $129K | 3/6/2026 | View on chart |
| RARE | ▼ Sell | Open Market | 8,135 | $185K | 3/2/2026 | View on chart |
| RARE | ▲ Buy | Grant | 11,137 | $0 | 3/1/2026 | View on chart |
| EOLS | ▲ Buy | Grant | 45,559 | $0 | 2/17/2026 | View on chart |
| RARE | ▼ Sell | Open Market | 2,450 | $76K | 9/12/2025 | View on chart |
| EOLS | ▼ Sell | Open Market | 12,888 | $167K | 3/12/2025 | View on chart |
| EOLS | ▲ Buy | Grant | 7,364 | $0 | 3/7/2025 | View on chart |
| RARE | ▼ Sell | Open Market | 12,846 | $541K | 3/3/2025 | View on chart |
| RARE | ▲ Buy | Grant | 14,494 | $0 | 3/1/2025 | View on chart |
| RARE | ▲ Buy | Grant | 18,443 | $0 | 3/1/2025 | View on chart |
| RARE | ▼ Sell | Open Market | 2,230 | $96K | 2/27/2025 | View on chart |
| RARE | ▼ Sell | Open Market | 760 | $32K | 2/27/2025 | View on chart |
| RARE | ▼ Sell | Open Market | 9,806 | $441K | 6/12/2024 | View on chart |
| RARE | ▲ Buy | Grant | 17,800 | $0 | 3/1/2024 | View on chart |
| RARE | ▲ Buy | Grant | 957 | $0 | 3/1/2024 | View on chart |
| RARE | ▼ Sell | Open Market | 3,756 | $202K | 3/1/2024 | View on chart |
| EOLS | ▲ Buy | Grant | 6,464 | $0 | 2/7/2024 | View on chart |
| EOLS | ▼ Sell | Open Market | 11,931 | $157K | 1/30/2024 | View on chart |
| RARE | ▼ Sell | Open Market | 4,378 | $197K | 5/4/2023 | View on chart |
| RARE | ▲ Buy | Grant | 2,663 | $0 | 3/1/2023 | View on chart |
| RARE | ▲ Buy | Grant | 22,000 | $0 | 3/1/2023 | View on chart |
| RARE | ▼ Sell | Open Market | 3,161 | $143K | 3/1/2023 | View on chart |
| EOLS | ▲ Buy | Grant | 8,293 | $0 | 1/27/2023 | View on chart |
| RARE | ▼ Sell | Open Market | 5,140 | $324K | 3/7/2022 | View on chart |
| RARE | ▼ Sell | Open Market | 2,886 | $192K | 3/1/2022 | View on chart |
| RARE | ▲ Buy | Grant | 14,000 | $0 | 3/1/2022 | View on chart |
| EOLS | ▲ Buy | Grant | 15,568 | $0 | 1/24/2022 | View on chart |
| RARE | ▼ Sell | Open Market | 310 | $25K | 10/14/2021 | View on chart |
| RARE | ▲ Buy | Option Exercise | 7,336 | $400K | 9/8/2021 | View on chart |
| RARE | ▼ Sell | Open Market | 7,336 | $738K | 9/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RARE FDA approves Fayuvi, triggers $203M voucher sale
Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.
RARE FDA approves Fayuvi, triggers $203M voucher sale. Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.